One in four people over 65 will have a stroke. Most will survive, but survival doesn’t mean recovery. While we’ve built data centers in space, stroke patients are still treated with 19th-century physical therapy.

In this episode of Machine Dreams, we sit down with Yotam Drechsler, CEO of BrainQ, who’s building what he calls “NVIDIA for brain recovery.” His AI-powered platform retrains neural networks damaged by stroke, helping patients recover at home through personalized electromagnetic fields and telemedicine.

Yotam explains why AI started in neuroscience but left the brain behind, why the first weeks after stroke matter so much, and what “responsible AI” actually means when patients are elderly, fragile, and trying to regain the ability to button their own shirt. We push back on the fear of AI replacing doctors and ask how you balance innovation with patient safety when families must trust an algorithm with their most precious asset.

This is AI beyond the demo—where the stakes are personal, timelines span decades of R&D, and getting it wrong means more than a bad user review.

AI is moving fast into healthcare, but the brain is not just another system to optimize. It’s fragile, personal, and deeply human.

In this episode of Machine Dreams, we speak with Yotam Drechsler, CEO of BrainQ, about what it really takes to use AI in brain recovery. We talk about stroke, neuroplasticity, why most care still looks like the 19th century, and why responsible AI sometimes means using less of it.

In this episode of Machine Dreams, we sit down with Judah Taub, Co-founder and Managing Partner at Hetz Ventures, fresh off closing the firm’s $140M Fund IV during wartime and a period of global uncertainty. Hetz now manages close to $500M in assets, and Judah has a front-row view into what serious investors are funding in AI and what they are walking away from.

We talk about why Judah sees this moment as the internet in the late 1990s, why “AI bubble” is really two different debates, and what separates durable AI businesses from fast demos. He breaks down the signals he watches, including a sharp test most founders don’t like to hear: does GPT-X make you obsolete, or does it make you stronger? We also unpack why infrastructure and deep software still win in Israel, what “color of revenue” means in practice, and where returns may actually accrue over the next five years as AI fragments into large models beyond language.

If you’re building, investing, or trying to understand where the real money is going in AI, this is the conversation that cuts through the noise.

AI spending isn’t dropping. Investors are just getting smarter about where it goes.

That’s what Judah Taub, founder and managing partner at Hetz Ventures, tells us in this episode of Machine Dreams.

Fresh off a $140 million fourth fund, Judah explains what VCs are funding now, what signals separate real revenue from hype, and the test that can make or break an AI startup.

If you’re building, investing, or trying to understand where the money is going in AI, do NOT miss this one!

We are now 4000+ subscribers strong and that’s only because of you, our dear viewers and subscribers. We’ve had some of the most forward-thinking minds in the AI industry as guests and the feedback on every episode has been remarkably amazing.

As we get ready to publish episode 7 next week, we wanted to share some of our favorite moments (really hard to choose, to be honest) from each episode so far.

AI is often talked about as if it can instantly diagnose illness, replace doctors, and see everything humans miss. In healthcare, that belief can be dangerous.

In this episode of Machine Dreams, we sit down with Moshe Barel, CEO and co-founder of AccuLine, to unpack how AI is actually used in real clinical settings. Moshe has spent more than two decades in cardiovascular medicine and digital health, and his company is building a non-invasive AI-powered system for the early detection of coronary artery disease.

We talk about what AI really does inside medical diagnostics, why human-designed algorithms still matter, how regulation shapes what can safely reach patients, and why most healthcare AI is nothing like ChatGPT. From FDA approval to biased data to the myths that won’t go away, this is a grounded conversation about where AI genuinely helps, where it does not, and what it takes to build systems doctors can trust.

AI in healthcare is often described like it’s some magic. It isn’t.

In this episode of Machine Dreams, AccuLine CEO Moshe Barel explains how medical AI actually works, why human oversight matters, and what it really takes to build diagnostic tools doctors can trust.

Everyone wants to add AI to their products right now. But few stop to ask whether it actually belongs there.

In the last episode of Machine Dreams for 2025, we speak with Josh Hart, co-founder and Chief Product and Technology Officer at YuLife, about what really matters before AI ever enters the picture. Josh has been building digital products since childhood and now leads a prevention-first insurance platform focused on health, trust, and long-term behavior change.

This conversation is not about models, prompts, or buzzwords. It is about design. It is about emotion. It is about understanding how people actually experience technology and why most AI features fail not because the tech is bad, but because the product thinking is.

We talk about why AI should often stay invisible, how gamification and user experience shape healthier behavior, what trust means when AI touches health and finance, and where founders go wrong when they treat AI as the product instead of a tool.

If you are building with AI or thinking about it, this episode will make you pause. And that pause might save you from building the wrong thing.

Everyone seems to be adding AI to their products. But very few stop to ask the harder question if it should even be there in the first place.

In this final episode of 2025, we sit down with Josh Hart, co-founder and Chief Product and Technology Officer at YuLife, to talk about what really matters before you add AI.

If you are building with AI in the new year, this is the pause you should take before you move forward.

Full episode out today.

7pm GMT+1. 6pm UK. 1pm EST.

Watch out!

Everyone is asking whether AI is in a bubble. Fewer people are asking the right question.

In this episode of Machine Dreams, we sit down with Guy Dassa, Investment Partner at OurCrowd, Israel’s most active VC with over $2 billion assets under management, and head of its AI portfolio, to unpack what is really happening behind today’s AI investment frenzy.

From infrastructure and foundational layers to applications, valuations, and so-called “round-tripping,” Guy explains why AI is not a repeat of the dot-com era and where long-term value is actually being built.

We explore how serious investors think about hype versus fundamentals, why picks-and-shovels matter more than headline apps, how Israel fits into the global AI ecosystem, and what founders need to understand if they want to raise capital in 2025 and beyond.

This is a rare, candid look at AI investing from someone deep inside the market.